BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2017. The put-call ratio across all filers is 0.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2017 | $1,943,000 | -33.9% | 349,500 | -0.1% | 0.03% | -33.3% |
Q1 2017 | $2,940,000 | +15.3% | 350,000 | -13.1% | 0.04% | +21.9% |
Q4 2016 | $2,549,000 | +59.2% | 402,600 | +10.9% | 0.03% | +88.2% |
Q3 2016 | $1,601,000 | +114.3% | 363,100 | +38.0% | 0.02% | +112.5% |
Q2 2016 | $747,000 | +0.3% | 263,100 | 0.0% | 0.01% | +33.3% |
Q1 2016 | $745,000 | – | 263,100 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |